Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Higher-dose weight loss injections now available." A new study increases max-dose guidance for semaglutide. This offers hope for those who didn’t reach their weight goals. The Injection and ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that ... and 3.9% with placebo. The increase in weight loss with the higher dose was impressive ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Semaglutide prescription initiation predictors included female sex and use of antidepressants among patients with obesity without diabetes.

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.